March 25, 2024 07:11 AM EDT
Pharma
FDA+

J&J's Acte­lion buy­out pays off again with ap­proval of Op­syn­vi in pul­monary ar­te­r­i­al hy­per­ten­sion

Katherine Lewin

News Reporter

John­son & John­son scored an FDA ap­proval for Op­syn­vi, a com­bo of the en­dothe­lin re­cep­tor an­tag­o­nist Op­sum­it and the phos­pho­di­esterase 5 in­hibitor tadalafil, for the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times